Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278798 | 0.85 | ALDH1A1 (0.61) | GABRA1GABRB2CA1CA2CYP3A4 | |
| SCHEMBL3807248 | 0.85 | ALDH1A1 (0.53) | GABRA1GABRB2CA1CA2CYP3A4 | |
| SCHEMBL5788396 | 0.83 | RXRA (0.45) | GABRA1GABRB2CA1CA2CYP3A4 | |
| SCHEMBL29890062 | 0.83 | RXRA (0.45) | GABRA1GABRB2CA1CA2CYP3A4 | |
| Phenol SCHEMBL28108070 | 0.82 | CYP3A4 (0.50) | GABRA1GABRB2CA1CA2CYP3A4 | |
| Flamenol SCHEMBL69428 | 0.80 | CYP3A4 (0.62) | GABRA1GABRB2CA1CA2CYP3A4 | |
| SCHEMBL233829 | 0.80 | ALDH1A1 (0.69) | GABRA1GABRB2CA1CA2CYP3A4 | |
| SCHEMBL18268 | 0.80 | GABRA1 (1.00) | GABRA1GABRB2CA1CA2CYP3A4 | |
| SCHEMBL123887 | 0.80 | GABRA1 (0.88) | GABRA1GABRB2CA1CA2CYP3A4 | |
| SCHEMBL5546107 | 0.79 | CYP1A1 (0.46) | GABRA1GABRB2CA1CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015645-A1 | SUBSTITUTED PYRAN DERIVATIVES | UNIV WAYNE STATE (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015645-A1 | SUBSTITUTED PYRAN DERIVATIVES | UNIV WAYNE STATE (US) | 2017-01-19 | — | — | US | disclosed |
| US-9458124-B2 | Substituted pyran derivatives | WAYNE STATE UNIVERSITY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20140309427-A1 | Substituted Pyran Derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-16 | — | — | US | disclosed |
| US-8394794-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-03-12 | — | — | US | disclosed |
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| EP-2303857-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20100197686-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2010003976-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-01-14 | — | — | WO | disclosed |
| EP-1554296-B1 | RACEMOSELECTIVE PREPARATION OF ISOLABLE ANSA-METALLOCENE BIPHENOXIDE COMPLEXES | BASELL POLYOLEFINE GMBH (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-7193099-B2 | Racemoselective preparation of isolable ansa-metallocene biphenoxide complexes | BASELL POLYOLEFINE GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| US-20060052587-A1 | Racemoselective preparation of isolable ansa-metallocene biphenoxide complexes | BASELL POLYOLEFINE GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1554296-A1 | RACEMOSELECTIVE PREPARATION OF ISOLABLE ANSA-METALLOCENE BIPHENOXIDE COMPLEXES | Basell Polyolefine GmbH (DE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037839-A1 | RACEMOSELECTIVE PREPARATION OF ISOLABLE ANSA-METALLOCENE BIPHENOXIDE COMPLEXES | BASELL POLYOLEFINE GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015645-A1 | SUBSTITUTED PYRAN DERIVATIVES | SLC18A2, SLC6A4, SLC6A3 | GABRA1 1769/4885GABRB2 1055/4885CA1 4210/4885 |
| US-20140309427-A1 | Substituted Pyran Derivatives | SLC18A2, SLC6A4, SLC6A3 | GABRA1 1769/4885GABRB2 1055/4885CA1 4210/4885 |
| US-20100197686-A1 | THERAPEUTIC COMPOUNDS | ABCC1, ABCB1, MCL1 | GABRA1 4314/4885GABRB2 3411/4885CA1 2114/4885 |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | GABRA1 433/4885GABRB2 211/4885CA1 169/4885 |
| US-20060052587-A1 | Racemoselective preparation of isolable ansa-metallocene biphenoxide complexes | ITPA, NBAS, ARSA | GABRA1 3661/4885GABRB2 4526/4885CA1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.